A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients-Reference-Cited by-同舟云学术

A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients

Published:2023-02-01 Issue:2 Volume:62 Page:126-133
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Due Asbjørn¹^ORCID,Berg Tobias¹²^ORCID,Jensen Maj-Britt¹,Yammeni Sophie³,Volmer Lone⁴,Brems-Eskildsen Anne Sofie⁵,Andersen Klaus Kaae⁶,Rana Saeeda⁷,Knoop Ann²,Kümler Iben⁸

Affiliation:

1. Danish Breast Cancer Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

2. Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

3. Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

4. Department of Oncology, Sygehus Lillebælt Syddansk Universitets Hospital, Vejle Sygehus, Denmark

5. Department of Oncology, Aarhus Universitet Hospital, Aarhus, Denmark

6. AstraZeneca Nordic, Copenhagen, Denmark

7. Daiichi-Sankyo Nordics ApS, Munchen, Denmark

8. Department of Oncology, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark

Funder

The Danish Cancer Society

AstraZeneca

Publisher

Medical Journals Sweden AB

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2023.2176257

Reference17 articles.

1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

2. Breast Cancer Treatment

3. Risk factors for the development of brain metastases in patients with HER2-positive breast cancer

4. Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer

5. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer